Stoke Therapeutics, Inc.
ANTISENSE OLIGOMERS FOR TREATMENT OF AUTOSOMAL DOMINANT MENTAL RETARDATION-5 AND DRAVET SYNDROME
Last updated:
Abstract:
Provided herein are methods and compositions for treating a subject in need thereof, such as a subject with deficient SYNGAP1 protein or SCN1A protein expression or a subject having AD mental retardation 5 or Dravet syndrome.
Status:
Application
Type:
Utility
Filling date:
23 Jun 2021
Issue date:
24 Mar 2022